Skip to navigation Skip to content

About MS

MS overview, disease courses, epidemiology and theories of causation

Diagnosis & Management Healthcare Professional App

Download this unique, FREE tool and resource that provides important information about the diagnosis and management of multiple sclerosis for practicing clinicians. The App is a concise compilation of current, easy-to-reference, evidence-based information that you can access at no charge as an Apple, Droid and Windows "App".

App production made possible by Allergan, Bayer HealthCare, Novartis and Questcor Pharmaceuticals, Inc.

Download for iPhone

Download for Android

Download for Windows Phone


Multiple sclerosis (MS) is a chronic, inflammatory disease of unknown etiology that involves an immune-mediated attack on the central nervous system. Central myelin and the oligodendrocytes that form central myelin appear to be the primary targets of the inflammatory attack, although the axons themselves are also damaged. The inflammatory attack on CNS white matter is associated with TH-1 and TH-17 cells and the loss of function of regulatory T cells. Gray matter lesions also occur early in the disease, and may even precede damage to the white matter (Popescu & Lucchinetti, 2012; Lucchinetti et al., 2011) in some individuals. The collective damage to white and gray matter results in a broad spectrum of clinical signs and symptoms.

The disease is thought to be precipitated by a combination of one or more environmental triggers acting in a genetically susceptible individual.

In most patients, MS begins with a relapsing-remitting course (RRMS) that eventually transitions to a more steadily progressive course -- secondary-progressive MS (SPMS). The onset of SPMS appears to be a dominant determinant of long-term disease prognosis (Scalfari et al., 2010). Male sex, older age at disease onset, and a higher number of early relapses are associated with a higher probability of progressive disease and shorter time to SPMS (Scalfari et al., 2013). A prediction model based on age, cortical lesion load, and cerebellar cortical volume has been offered to explain the probability of evolving to SPMS, with gray matter damage appearing to play a pivotal role (Calabrese et al., 2013). Preventing the onset of SPMS is a primary target of treatment at this time (Scalfari et al., 2013). In a much smaller percentage of patients, the disease is progressive from onset (primary-progressive MS).


Become a Research Champion

An MS Research Revolution

Support MS Research

Understanding and ending MS can’t come fast enough – it will take all of us working together. It’s easy to be a champion for MS Research – join us and proudly let everyone know that you’re helping to lead the MS Research Revolution.

Become a Research Champion

Become a Research Champion